Shield Therapeutics（STX）株式概要
シールド・セラピューティクス社は、商業段階のスペシャリティ・ファーマであり、アンメット・メディカル・ニーズを治療する医薬品の商業化に注力している。 詳細
STX Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.3% 割安 内在価値ディスカウント
5022.2%Revenue growth p.a.
3.7k
23
2
54
Shield Therapeutics plc 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | UK£0.079 |
| 52週高値 | UK£0.13 |
| 52週安値 | UK£0.022 |
| ベータ | 1.91 |
| 1ヶ月の変化 | -11.73% |
| 3ヶ月変化 | -26.51% |
| 1年変化 | 229.17% |
| 3年間の変化 | 5.33% |
| 5年間の変化 | -83.54% |
| IPOからの変化 | -94.97% |
最新ニュース
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
Apr 12
Recent updates
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
Apr 12STX: Pediatric And China Approvals Will Expand Future Earnings Power
Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.
STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside
Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.STX: Pediatric Expansion And China Filing Will Redefine Earnings Power
Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential
Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside
Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).STX: Pediatric Expansion And New Market Approvals Will Support Future Upside
Analysts have lifted their price target on Shield Therapeutics from £0.16 to about £0.17, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What’s in the News US FDA grants priority review approval to extend ACCRUFeR’s indication to adolescents, covering iron deficiency treatment in patients 10 years and older, backed by positive Phase 3 pediatric trial data (FORTIS/ST10-01-305) (Key Developments).STX: Expanded Pediatric And Global Approvals Will Support Future Upside
Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.STX: Future US Label Expansion Could Still Leave Shares Vulnerable
Analysts have raised their price target for Shield Therapeutics from 0.03 dollars to 0.10 dollars, citing slightly stronger long term revenue growth expectations, while applying a higher discount rate and more conservative profit margin and valuation multiples. What's in the News Presentation of pediatric FORTIS PK sub study at the American Society of Hematology conference in December 2025 showed ferric maltol is well absorbed across pediatric age groups, with maltol rapidly metabolized and excreted, supporting its suitability for iron replacement in children and adolescents (company announcement).STX: New Regulatory Approvals And Pediatric Data Will Drive Future Upside
Analysts have modestly increased their price target on Shield Therapeutics, citing slightly stronger projected revenue growth, a marginally lower profit margin, and a modestly higher future price-to-earnings multiple. What's in the News The Korean Ministry of Food and Drug Safety granted regulatory approval for ACCRUFeR (ferric maltol) in adults with iron deficiency, opening a new commercial market and triggering eligibility for milestones and royalties (company announcement).Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity
Nov 25STX: FDA Priority Review and Regulatory Approvals Will Drive Significant Upside
Analysts have modestly raised their price target for Shield Therapeutics from $0.16 to $0.16 per share. This change reflects updated assumptions around discount rates and profit margins, while maintaining a cautiously optimistic outlook.STX: Upcoming FDA Decision Will Drive Confidence After Positive Pediatric Results
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation. What's in the News Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference.Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Narrative Update on Shield Therapeutics: Analyst Price Target Revision Analysts have maintained their price target for Shield Therapeutics at £0.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.Global Aging Trends And Early Detection Will Unlock Markets
Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts. What's in the News Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).The Market Lifts Shield Therapeutics plc (LON:STX) Shares 76% But It Can Do More
Aug 23Global Aging Trends And Early Detection Will Unlock Markets
An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product.Shield Therapeutics plc (LON:STX) Soars 27% But It's A Story Of Risk Vs Reward
Jun 28Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Feb 06Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22株主還元
| STX | GB Pharmaceuticals | GB 市場 | |
|---|---|---|---|
| 7D | -10.7% | -3.8% | -0.2% |
| 1Y | 229.2% | 20.6% | 19.7% |
業界別リターン: STX過去 1 年間で20.6 % の収益を上げたUK Pharmaceuticals業界を上回りました。
リターン対市場: STX過去 1 年間で19.7 % の収益を上げたUK市場を上回りました。
価格変動
| STX volatility | |
|---|---|
| STX Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.2% |
安定した株価: STXの株価は、 UK市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: STXの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2008 | 63 | Anders Lundstrom | www.shieldtherapeutics.com |
Shield Therapeutics plcはコマーシャルステージのスペシャリティファーマで、アンメットメディカルニーズを満たす医薬品の商業化に注力している。主力製品はAccrufer/Feraccruで、貧血を伴う、あるいは伴わない鉄欠乏症を治療する成人向けの非塩ベースの経口療法である。Shield Therapeutics plcは2008年に設立され、英国ゲーツヘッドに本社を置いている。
Shield Therapeutics plc 基礎のまとめ
| STX 基礎統計学 | |
|---|---|
| 時価総額 | UK£93.49m |
| 収益（TTM） | -UK£12.96m |
| 売上高(TTM) | UK£36.49m |
2.3x
P/Sレシオ-6.5x
PER（株価収益率STX は割高か？
公正価値と評価分析を参照収益と収入
| STX 損益計算書（TTM） | |
|---|---|
| 収益 | US$49.70m |
| 売上原価 | US$26.66m |
| 売上総利益 | US$23.04m |
| その他の費用 | US$40.69m |
| 収益 | -US$17.65m |
直近の収益報告
Dec 31, 2025
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.017 |
| グロス・マージン | 46.36% |
| 純利益率 | -35.52% |
| 有利子負債／自己資本比率 | -199.9% |
STX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/01 08:06 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Shield Therapeutics plc 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |